CAS 1086062-66-9 appears in our catalog under these names: GSK 2126458, >95% (HPLC), Omipalisib/ 99.16% (existing batch purity), GSK2126458, GSK 2126458, Omipalisib 98%. Offered by: TRC, TargetMol, GLPBio, Chemat, Biosynth. Available pack sizes: 10mg, 1mg, 5mg, 25mg, 50mg, 100mg, 10mM (in 1ml dmso), 2mg.
Omipalisib is a member of the class of quinolines that is quinoline which is substituted by pyridazin-4-yl and 5-[(2,4-difluorobenzene-1-sulfonyl)amino]-6-methoxypyridin-3-yl groups at positions 4 and 6, respectively. It is a highly potent inhibitor of PI3K and mTOR developed by GlaxoSmithKline and was previously in human phase 1 clinical trials for the treatment of idiopathic pulmonary fibrosis and solid tumors. It has a role as a radiosensitizing agent, an autophagy inducer, an anticoronaviral agent, an antifibrotic agent, an antineoplastic agent, an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor and a mTOR inhibitor. It is a member of pyridines, a member of quinolines, a sulfonamide, an aromatic ether, a member of pyridazines and a difluorobenzene.
Source: ChEBI
| Molecular formula | C25H17F2N5O3S |
|---|---|
| Molecular weight | 505.5 g/mol |
| IUPAC name | 2,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)-3-pyridinyl]benzenesulfonamide |
| InChIKey | CGBJSGAELGCMKE-UHFFFAOYSA-N |
| SMILES | COC1=C(C=C(C=N1)C2=CC3=C(C=CN=C3C=C2)C4=CN=NC=C4)NS(=O)(=O)C5=C(C=C(C=C5)F)F |
Computed by PubChem (NCBI)